Literature DB >> 19846279

Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels.

Francisco J Diaz1, Alexander Meary, Maria J Arranz, Gualberto Ruaño, Andreas Windemuth, Jose de Leon.   

Abstract

Acetyl-coenzyme A carboxylase alpha (ACACA) single-nucleotide polymorphism (SNP) (rs2229416) was significantly associated with hypertriglyceridemia, during exploration of antipsychotic direct effects on lipids. Neuropeptide Y (NPY) gene (rs1468271) and ACACB gene (rs2241220) SNPs were significantly associated with severe hypercholesterolemia. In the same sample (173 patients on olanzapine, quetiapine, chlorpromazine or mirtazapine [increasing the risk of hyperlipidemia] and 184 controls taking other antipsychotics), three (rs1266175, rs12453407 and rs9906543) of eight additional ACACA SNPs were significantly associated with hypertriglyceridemia in those taking drugs of interest, but not in controls. Five other ACACA SNPs, three additional NPY SNPs, and seven additional ACACB SNPs were not significant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846279      PMCID: PMC2784140          DOI: 10.1016/j.schres.2009.09.038

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  13 in total

1.  Changes in weight and glucose tolerance during treatment with mirtazapine.

Authors:  Hubertus Himmerich; Stephany Fulda; Ludwig Schaaf; Pierre A Beitinger; Andreas Schuld; Thomas Pollmächer
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

2.  Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.

Authors:  G Ruaño; J W Goethe; C Caley; S Woolley; T R Holford; M Kocherla; A Windemuth; J de Leon
Journal:  Mol Psychiatry       Date:  2007-01-02       Impact factor: 15.992

3.  Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.

Authors:  Courtney Markham-Abedi; Jose de Leon
Journal:  J Clin Psychiatry       Date:  2006-09       Impact factor: 4.384

4.  Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy.

Authors:  Jose de Leon; Francisco J Diaz
Journal:  Schizophr Res       Date:  2007-07-06       Impact factor: 4.939

5.  Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.

Authors:  Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

Review 6.  The effects of antipsychotic therapy on serum lipids: a comprehensive review.

Authors:  Jonathan M Meyer; Carol E Koro
Journal:  Schizophr Res       Date:  2004-09-01       Impact factor: 4.939

7.  Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report.

Authors:  Julie L Chen; Noam Spinowitz; Manoj Karwa
Journal:  Pharmacotherapy       Date:  2003-07       Impact factor: 4.705

8.  DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.

Authors:  J Popp; S Leucht; S Heres; W Steimer
Journal:  Pharmacogenomics J       Date:  2008-03-11       Impact factor: 3.550

Review 9.  Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.

Authors:  M J Arranz; J de Leon
Journal:  Mol Psychiatry       Date:  2007-06-05       Impact factor: 15.992

10.  A clinical study of the association of antipsychotics with hyperlipidemia.

Authors:  Jose de Leon; Margaret T Susce; Maria Johnson; Mike Hardin; Lana Pointer; Gualberto Ruaño; Andreas Windemuth; Francisco J Diaz
Journal:  Schizophr Res       Date:  2007-03-08       Impact factor: 4.939

View more
  6 in total

Review 1.  Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.

Authors:  Hu Yan; Jin-Dong Chen; Xiao-Yan Zheng
Journal:  Psychopharmacology (Berl)       Date:  2013-07-06       Impact factor: 4.530

2.  Polymorphisms, de novo lipogenesis, and plasma triglyceride response following fish oil supplementation.

Authors:  Annie Bouchard-Mercier; Iwona Rudkowska; Simone Lemieux; Patrick Couture; Marie-Claude Vohl
Journal:  J Lipid Res       Date:  2013-07-25       Impact factor: 5.922

3.  Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.

Authors:  Andreas Windemuth; Jose de Leon; John W Goethe; Harold I Schwartz; Stephen Woolley; Margaret Susce; Mohan Kocherla; Kali Bogaard; Theodore R Holford; Richard L Seip; Gualberto Ruaño
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-08-06       Impact factor: 5.067

Review 4.  Structure and function of biotin-dependent carboxylases.

Authors:  Liang Tong
Journal:  Cell Mol Life Sci       Date:  2012-08-07       Impact factor: 9.261

5.  Latent, sex-specific metabolic health effects in CD-1 mouse offspring exposed to PFOA or HFPO-DA (GenX) during gestation.

Authors:  Harlie A Cope; Bevin E Blake; Charlotte Love; James McCord; Susan A Elmore; Janice B Harvey; Vesna A Chappell; Suzanne E Fenton
Journal:  Emerg Contam       Date:  2021-10-31

6.  Role of Statistical Random-Effects Linear Models in Personalized Medicine.

Authors:  Francisco J Diaz; Hung-Wen Yeh; Jose de Leon
Journal:  Curr Pharmacogenomics Person Med       Date:  2012-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.